Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Silence Therapeutics (SLN) EBITDA Margin: 2019-2024

Historic EBITDA Margin for Silence Therapeutics (SLN) over the last 6 years, with Dec 2024 value amounting to 146.38%.

  • Silence Therapeutics' EBITDA Margin fell 1450319.00% to 16,505.66% in Q3 2025 from the same period last year, while for Sep 2025 it was 321.21%, marking a year-over-year increase of 11438.00%. This contributed to the annual value of 146.38% for FY2024, which is 5709.00% up from last year.
  • Silence Therapeutics' EBITDA Margin amounted to 146.38% in FY2024, which was up 28.06% from 203.47% recorded in FY2023.
  • Silence Therapeutics' EBITDA Margin's 5-year high stood at 146.38% during FY2024, with a 5-year trough of 654.26% in FY2020.
  • Its 3-year average for EBITDA Margin is 210.57%, with a median of 203.47% in 2023.
  • Per our database at Business Quant, Silence Therapeutics' EBITDA Margin soared by 866,295bps in 2020 and then tumbled by 5,709bps in 2024.
  • Over the past 5 years, Silence Therapeutics' EBITDA Margin (MRY) stood at 654.26% in 2020, then surged by 44bps to 369.02% in 2021, then rose by 24bps to 281.87% in 2022, then grew by 28bps to 203.47% in 2023, then increased by 28bps to 146.38% in 2024.
  • Its EBITDA Margin stands at 146.38% for FY2024, versus 203.47% for FY2023 and 281.87% for FY2022.